LexaGene Announces Results of Annual General and Special Meeting
December 17 2021 - 1:08PM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company
that has commercialized an instrument for automated multiplex PCR
testing, is pleased to announce the voting results of the Company’s
2021 Annual General Special Meeting (the
“
Meeting”) held on December 16, 2021 in Vancouver,
British Columbia.
A total of 50,094,097 common shares were voted at the Meeting,
representing 41.97% of the votes attached to all outstanding common
shares of the Company.
All matters presented for shareholder approval at the Meeting
were duly authorized and approved as follows:
- To set the number of Directors to
be elected at five.
- Election of Directors.
- The appointment of RSM US LLP,
Certified Public Accountants, as auditor of the Company for the
ensuing year.
- The adoption by the Company of New
Articles.
- Increase the number of Common
Shares available for conversion of Restricted Share Units.
- Increase the number of Common
Shares available for exercise of Options
Detailed voting results for the election of directors were as
follows:
Name |
Shares Voted For |
% |
Shares Withheld / Abstain |
% |
Dr. John (Jack) Regan |
23,261,101 |
95.39 |
1,123,964 |
4.61 |
Stephen Mastrocola |
23,184,814 |
95.40 |
1,117,128 |
4.60 |
Thomas Richard Slezak |
23,241,987 |
95.31 |
1,143,078 |
4.69 |
Dr. Jane Sykes |
23,222,315 |
95.23 |
1,162,750 |
4.77 |
Joseph Caruso |
23,088,689 |
94.68 |
1,296,376 |
5.32 |
For further details regarding the voting results of the Meeting,
please refer to the Company’s Report of Voting Results filed on
SEDAR at www.sedar.com
To be added to the LexaGene email list, please subscribe on the
Company website.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
Corporate & Media Contact:Gail
WinslowDirector, Marketinggwinslow@lexagene.com978.482.6237
Investors:ir@lexagene.com800.215.1824
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024